Diagnostic efficiency of systemic immune-inflammation index in fusion prostate biopsy

Sönmez, Gökhan; Demirtaş, Türev; Tombul, Şevket Tolga; Akgün, Hülya; Demirtaş, Abdullah

doi:10.1016/j.acuroe.2021.04.006

Cited by 11 publications

(18 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition to the predictive role in prognosis, Sonmez et al found that SII also plays a role in the diagnosis of PCa. SII had significant diagnostic value in PCa patients with an ISUP grade ≥3, the combination of SII with the PI-RADS score might be the most effective marker to diagnose PCa ( 41 ). Wang et al also found that patients with PCa had significantly higher SII than those diagnosed with benign prostatic hyperplasia ( 42 ).…”

Section: Discussionmentioning

confidence: 99%

Revealing the prognostic and clinicopathological significance of systemic immune-inflammation index in patients with different stage prostate cancer: A systematic review and meta-analysis

Zhou²,

Liu³

et al. 2022

Front. Med.

View full text Add to dashboard Cite

BackgroundA novel inflammatory marker called the systemic immune-inflammation index (SII) was applied to predict the prognosis of different cancers. However, the role of SII in prostate cancer (PCa) remains unclear. This systematic review aims to explore the prognostic role of SII in different stage PCa.MethodsWe comprehensively searched three public databases: PubMed, EMBASE, and the Cochrane Library. The hazard ratios (HRs) and odds ratios (ORs) with 95% confidence intervals (CIs) were extracted to evaluate the association between SII and the prognosis and clinicopathological characteristics in different stage PCa patients.ResultsTen studies and 7,986 patients were enrolled in our meta-analysis, 1,442 patients were diagnosed with metastatic-castration resistant prostate cancer (mCRPC), and 6544 patients were diagnosed with non-metastatic prostate cancer (nmPCa). According to the pooled results, we found that a high SII was associated with worse overall survival (OS) in mCRPC patients (HR = 1.94, 95% CI: 1.26–3.01, p = 0.003), and a high SII was associated with biochemical recurrence-free survival (BFS) in nmPCa patients (HR = 1.85, 95% CI: 1.06–3.24, p = 0.031). But there was no significant association observed between SII and progression-free survival (PFS) in mCRPC patients (HR = 1.90, 95% CI: 0.87–4.14, p = 0.107). And we found that the high SII was associated with advanced tumor stage of PCa (OR = 2.19, 95% CI: 1.11–4.33, p = 0.024), presence of lymph node involvement (OR = 2.72, 95% CI: 1.96–3.76, p < 0.001) and Gleason score (OR = 1.27, 95% CI: 1.13–1.44, p < 0.001).ConclusionHigh SII was associated with bad OS in mCRPC patients, and associated with bad BFS and some adverse pathological features in nmPCa patients. We think SII can be a prognostic predictor for PCa patients. The application of SII will advance the diagnosis and treatment of different stage prostate cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Revealing the prognostic and clinicopathological significance of systemic immune-inflammation index in patients with different stage prostate cancer: A systematic review and meta-analysis

Zhou²,

Liu³

et al. 2022

Front. Med.

View full text Add to dashboard Cite

show abstract

“…These inflammatory cells and cytokines constitute the tumor microenvironment which promote tumourigenesis and progression by navigating the immunoregulatory network, phenotypic epithelial-mesenchymal transition (EMT), angiogenesis, and anoikis resistance 36 . While NLR and PLR are conventional inflammatory indicators [37][38][39] , SII, a new inflammatory index, appears to be a more powerful predictor of tumors than NLR and PLR 14,15 . Wang et al 40 found SII ≥ 471.86 (OR = 1.694; 95% CI 1.122-2.558; P = 0.003) was an independent risk factor and concluded that SII is the most powerful indicator among NLR, PLR, and SII in terms of their associations with PCa.…”

Section: Discussionmentioning

confidence: 94%

Prebiopsy bpMRI and hematological parameter-based risk scoring model for predicting outcomes in biopsy-naive men with PSA 4–20 ng/mL

Zheng

Zhang

et al. 2022

Sci Rep

View full text Add to dashboard Cite

Excessive prostate biopsy is a common problem for clinicians. Although some hematological and bi-parametric magnetic resonance imaging (bpMRI) parameters might help increase the rate of positive prostate biopsies, there is a lack of studies on whether their combination can further improve clinical detection efficiency. We retrospectively enrolled 394 patients with PSA levels of 4–20 ng/mL who underwent prebiopsy bpMRI during 2010–2021. Based on bpMRI and hematological indicators, six models and a nomogram were constructed to predict the outcomes of biopsy. Furthermore, we constructed and evaluated a risk scoring model based on the nomogram. Age, prostate-specific antigen (PSA) density (PSAD), systemic immune-inflammation index, cystatin C level, and the Prostate Imaging Reporting and Data System (PI-RADS) v2.1 score were significant predictors of prostate cancer (PCa) on multivariable logistic regression analyses (P < 0.05) and the five parameters were used to construct the XYFY nomogram. The area under the receiver operating characteristic (ROC) curve (AUC) of the nomogram was 0.916. Based on the nomogram, a risk scoring model (XYFY risk model) was constructed and then we divided the patients into low-(XYFY score: < 95), medium-(XYFY score: 95–150), and, high-risk (XYFY score: > 150) groups. The predictive values for diagnosis of PCa and clinically-significant PCa among the three risk groups were 3.0%(6/201), 41.8%(51/122), 91.5%(65/71); 0.5%(1/201), 19.7%(24/122), 60.6%(43/71), respectively. In conclusion, in this study, we used hematological and bpMRI parameters to establish and internally validate a XYFY risk scoring model for predicting the biopsy outcomes for patients with PSA levels of 4–20 ng/mL and this risk model would support clinical decision-making and reduce excessive biopsies.

show abstract

“…It is also important to consider that combining preoperative plasma endoglin with other blood‐based biomarkers is more likely to capture a higher predictive value than any single biomarkers. 9 , 19 , 37 , 38 Additionally, its combination with tissue expression of endoglin, as a marker of angiogenesis, in a specimen from transurethral resection of bladder tumor might help in preoperative patient counseling, especially in patients with papillary noninvasive bladder cancer as a tumor with well‐developed branching fibrovascular core. Urothelium endoglin antibodies have been shown to recognize small‐caliber vessels that are associated with angiogenesis in bladder cancer that can help identify high‐risk patients who could benefit from antiangiogenic therapeutic regimens.…”

Section: Discussionmentioning

confidence: 99%

Preoperative plasma level of endoglin as a predictor for disease outcomes after radical cystectomy for nonmetastatic urothelial carcinoma of the bladder

Laukhtina

Schuettfort

D’Andrea

et al. 2021

Molecular Carcinogenesis

View full text Add to dashboard Cite

Elevated preoperative plasma level of endoglin has been associated with worse oncologic outcomes in various malignancies. The present large-scale study aimed to determine the predictive and prognostic values of preoperative endoglin with regard to clinicopathologic and survival outcomes in patients treated with radical cystectomy (RC) for nonmetastatic urothelial carcinoma of the bladder (UCB). We prospectively collected preoperative blood samples from 1036 consecutive patients treated with RC for UCB. Logistic and Cox regression analyses were undertaken to assess the correlation of endoglin levels with pathologic and survival outcomes, respectively. The AUC and C-index were used to assess the discrimination. Patients with adverse pathologic features had significantly higher median preoperative endoglin plasma levels than their counterparts. Higher preoperative endoglin level was independently associated with an increased risk for lymph node metastasis, ≥pT3 disease, and nonorgan confined disease (NOCD; all p < 0.001).Plasma endoglin level was also independently associated with cancer-specific and overall survival in both pre-and postoperative models (all p < 0.05), as well as with recurrencefree survival (RFS) in the preoperative model (p < 0.001). The addition of endoglin to the preoperative standard model improved its discrimination for prediction of lymph node metastasis, ≥pT3 disease, NOCD, and RFS (differential increases in C-indices: 10%, 5%, 5.8%, and 4%, respectively). Preoperative plasma endoglin is associated with features of biologically and clinically aggressive UCB as well as survival outcomes. Therefore, it seems to hold the potential of identifying UCB patients who may benefit from intensified therapy in addition to RC such as extended lymphadenectomy or/and preoperative systemic therapy.

show abstract

Diagnostic efficiency of systemic immune-inflammation index in fusion prostate biopsy

Cited by 11 publications

References 26 publications

Revealing the prognostic and clinicopathological significance of systemic immune-inflammation index in patients with different stage prostate cancer: A systematic review and meta-analysis

Revealing the prognostic and clinicopathological significance of systemic immune-inflammation index in patients with different stage prostate cancer: A systematic review and meta-analysis

Prebiopsy bpMRI and hematological parameter-based risk scoring model for predicting outcomes in biopsy-naive men with PSA 4–20 ng/mL

Preoperative plasma level of endoglin as a predictor for disease outcomes after radical cystectomy for nonmetastatic urothelial carcinoma of the bladder

Contact Info

Product

Resources

About